Introduction: Immune checkpoint inhibitors (ICIs) have transformed the treatment of microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) metastatic colorectal cancer (mCRC). While pembrolizumab and nivolumab are established treatment options, recent evidence has raised interest in dual checkpoint blockade with nivolumab plus ipilimumab.
Introduction:
Immune checkpoint inhibitors (ICIs) have transformed the treatment of microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) metastatic colorectal cancer (mCRC). While pembrolizumab and nivolumab are established treatment options, recent evidence has raised interest in dual checkpoint blockade with nivolumab plus ipilimumab. In the absence of direct comparative trials, this study used reconstructed individual patient data to compare the efficacy and safety of dual versus single-agent ICI therapy.
Why was this study needed?
. No head-to-head trials compare pembrolizumab with nivolumab–ipilimumab in MSI-H/dMMR mCRC.
. Clinicians need evidence to guide the choice between single- and dual-agent immunotherapy.
. Indirect comparisons using reconstructed patient-level data can provide valuable comparative insights.
. Balancing efficacy against immune-related toxicity is critical for treatment selection.
Results:
Using reconstructed individual patient data from the KEYNOTE-177 and CheckMate 8HW trials, the analysis demonstrated that nivolumab plus ipilimumab was associated with longer progression-free survival than pembrolizumab. In contrast, single-agent nivolumab and pembrolizumab showed comparable progression-free survival, suggesting similar efficacy between PD-1 inhibitor monotherapy options. The reconstructed comparison between dual therapy and nivolumab alone closely mirrored the published CheckMate 8HW results, supporting the validity of the analytical approach. However, dual immune checkpoint blockade was associated with a higher incidence of grade 3–4 immune-mediated adverse events compared with nivolumab monotherapy, reflecting the expected trade-off between increased efficacy and greater toxicity.
Clinical Impact:
These findings support dual immune checkpoint blockade as a potentially more effective first-line strategy for selected patients with MSI-H/dMMR metastatic colorectal cancer, particularly those who can tolerate increased immune-related toxicity. For patients in whom toxicity is a major concern, pembrolizumab and nivolumab appear to offer comparable efficacy as single-agent therapy. Although hypothesis-generating, this analysis provides useful guidance where direct comparative trials are unlikely.
Bottom Line:
Dual nivolumab–ipilimumab may provide superior progression-free survival compared with pembrolizumab in MSI-H/dMMR metastatic colorectal cancer but at the cost of greater immune-related toxicity, while nivolumab and pembrolizumab monotherapy demonstrate similar efficacy.
Introduction: Immune checkpoint inhibitors have revolutionized the treatment of dMMR/MSI-H rectal cancer, but most patients worldwide continue to receive total neoadjuvant therapy (TNT) as standard care. This international real-world study evaluated whether mismatch repair (MMR)...
Introduction: Immune checkpoint inhibitors (ICIs) are the standard first-line treatment for MSI-H/dMMR metastatic colorectal cancer (mCRC). In the absence of direct head-to-head trials, this reconstructed individual patient data (IPD) analysis compared nivolumab–ipilimumab, nivolumab, and pembrolizumab...
Introduction: Neuroendocrine liver metastases (NELM) are a major determinant of morbidity and mortality in patients with neuroendocrine neoplasms. Over the past three decades, advances in imaging, systemic therapies, radionuclide treatment, and liver-directed interventions have expanded...
Introduction: Pathological complete response (pCR) following neoadjuvant therapy is considered a favorable prognostic marker in esophageal adenocarcinoma. However, whether patients achieving pCR derive similar long-term benefit regardless of the neoadjuvant regimen remains uncertain. This multicenter...
Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...
Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.